Acquisition - February 18, 2022
Xbrane pauses negotiations with expected acquirer of Primm Pharma
Xbrane Biopharma’s efforts to divest the subsidiary Primm Pharma continues although negotiations with the previously expected acquirer NewFaDem for the time being has been paused. Primm Pharma is a fully owned subsidiary of Xbrane specialized in long-acting injectables and developer of Spherotide, a long-acting triptorelin formulation candidate intended to be used in treatment of prostate […]
Agreement - February 8, 2022
Xbrane Biopharma enters agreement with Biogen
The two companies have entered into a commercialization and license agreement to develop, manufacture, and commercialize Xcimzane, a preclinical monoclonal antibody that is a proposed biosimilar referencing CIMZIA. CIMZIA’s primary indication is for rheumatoid arthritis in adults as well as axial spondylarthrosis, psoriasis and Crohn’s disease. In 2020 global sales of CIMZIA were 1.8 billion […]
Agreement - October 7, 2021
Xbrane Biopharma enters agreement with AGC Biologics
Xbrane Biopharma and AGC Biologics, a global Biopharmaceutical CDMO, have entered into an agreement to manufacture Xcimzane, a Cimzia biosimilar candidate, for clinical development. Under terms of the agreement, the companies will work together to upscale the established Xcimzane manufacturing process and produce several commercial scale batches for upcoming phase I and phase III clinical […]
Clinical Trials - June 30, 2021
Xbrane’s Xlucane meets primary endpoint
Xbrane Biopharma has announced results from the six months interim read-out in the Phase III equivalence trial with the Lucentis biosimilar candidate Xlucane. Xlucane met the primary endpoint demonstrating equivalent efficacy in change of BCVA (Best Corrected Visual Acuity) at week 8 of treatment compared to Lucentis, states the company in a press release. Xbrane […]
Biotech Business - May 21, 2020
Xbrane raises 146 million SEK
The Board of Directors of Xbrane Biopharma has successfully completed a directed issue of 3,853,799 shares corresponding to approximately SEK 146 million before costs related to the transaction. The subscription price in the Directed Share Issue has been determined to 38 SEK per share through an accelerated book building procedure performed by Vator Securities AB. […]
Biotech Business - September 17, 2019
Xbrane to list on Nasdaq Stockholm
Nasdaq Stockholm’s listing committee has decided that Xbrane Biopharma AB fulfills the requirements for admission to trading of the company’s shares on the main market Nasdaq Stockholm. The first day of trading of Xbrane’s shares on Nasdaq Stockholm is expected to be Monday 23 September 2019. The last day of trading of Xbrane’s shares on […]
